Following the recommendations of the Food and Drug Administration, the Drug Enforcement Administration Dec. 19, 2012, proposed that a newly approved anti-obesity drug, lorcaserin, be put on Schedule IV control (77 Fed. Reg. 75075). Lorcaserin ((R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzepine hydrochloride hemihydrate) is a serotonin receptor agonist at the 5HT2C and 5HT2A r... Read More